03:53 , Sep 21, 2018 |  BC Innovations  |  Product R&D

China’s rising genomics start-ups

Behind bellwethers BGI Genomics Co. Ltd. and WuXi NextCode Genomics Inc., a new generation of Chinese genomics companies is emerging with ambitions to solve urgent problems, including early cancer detection and clinical trial recruitment, by...
18:46 , Sep 7, 2018 |  BioCentury  |  Emerging Company Profile

Leveraging cross-linking

Lyvgen Biopharma Co. Ltd. is using its xLinkAb platform to develop mAbs that agonize T cell or dendritic cell co-stimulatory receptors with better safety and selectivity for tumors than competing mAbs. According to founder and CEO...
11:04 , Sep 5, 2018 |  BioCentury  |  Finance

Fulcrum’s genetic levers

Fulcrum Therapeutics Inc.’s ability to identify targets for genetic disease drivers using bioinformatics prompted Foresite Capital to lead the company’s untranched $80 million series B round. Fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital,...
11:02 , Sep 5, 2018 |  BC Extra  |  Financial News

Fulcrum raises $80M series B

Fulcrum Therapeutics Inc. (Cambridge, Mass.) raised $80 million in an untranched series B round led by Foresite Capital. Also participating were fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital, Sanofi Venture, Section 32, NS...
18:47 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Harbin Gloria selling stake in biotech unit to new investors

Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) said Aug. 17 it plans to sell a 51% stake in biotech subsidiary Guangzhou Gloria Biotechnology Co. Ltd. (Guangzhou, China) to 6 Dimensions Capital, Boyu Capital and two other...
23:37 , Aug 17, 2018 |  BC Extra  |  Financial News

Harbin Gloria selling stake in biotech unit

Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437) said Friday it plans to sell a 51% stake in biotech subsidiary Guangzhou Gloria Biotechnology Co. Ltd. (Guangzhou, China) to 6 Dimensions Capital, Boyu Capital and two other investors. The...
16:42 , Aug 3, 2018 |  BC Week In Review  |  Financial News

6 Dimensions' imuno-oncology play Curon raises $150M series A

Curon Biopharmaceutical Ltd. (Shanghai, China) raised $150 million on July 27 in a series A round from 6 Dimensions Capital, Boyu Capital and Temasek. Curon will use the funds to expand its pipeline of next-generation immunotherapeutic...
21:56 , Jul 30, 2018 |  BC Extra  |  Financial News

6 Dimensions' immuno-oncology play Curon raises $150M series A

Curon Biopharmaceutical (Shanghai, China) raised $150 million in a series A round from 6 Dimensions Capital, Boyu Capital and Temasek. Curon will use the funds to expand its pipeline of next-generation immunotherapeutic cancer agents. 6 Dimensions,...
16:57 , Jul 20, 2018 |  BC Week In Review  |  Financial News

6 Dimensions leads Lyvgen's $30M series B

Lyvgen Biopharma Co. Ltd. (Shanghai, China) raised $30 million in a series B round led by 6 Dimensions Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated. Lyvgen is developing...
22:56 , Jul 16, 2018 |  BC Extra  |  Financial News

6 Dimensions leads Lyvgen's $30M series B

Lyvgen Biopharma Co. Ltd. (Shanghai, China) raised $30 million in a series B round led by 6 Dimensions Capital. New investors Winfair Global and Runling Capital and existing investor Morningside Ventures also participated. Lyvgen is developing...